GE Healthcare today announced FDA clearance for its new mammography Senographe Essential, the next-generation of the company’s full-field digital mammography (FFDM) systems.
The new Senographe Essential features a 24 x 31 cm detector size, and GE’s advanced digital detector, which at low doses delivers high Detective Quantum Efficiency (DQE), according to the company.
In a recent large-scale cancer screening trial published last September by the National Cancer Institute (NCI) and the American College of Radiology Imaging Network (ACRIN), GE’s Senographe digital mammography system was used for 44 percent more exams than any other digital system. The study reported that while film and digital images are equally accurate for many women, digital mammograms had higher sensitivities for three sub-groups of women: women under 50, women with heterogeneous or very dense breast tissue, and pre- or perimenopausal women.
GE introduced full-field digital mammography for patient use six years ago, and today there are more than 1,500 GE Senographe systems in use worldwide. Additionally, over 25 million women have been examined using GE Senographe FFDM systems, the company said.
The Senographe family of products was introduced in early 2004.